前交叉韧带重建后软骨代谢全身生物标志物异常值患者的探索
该队列研究纳入666例初次前交叉韧带重建患者,术前及术后6、12个月检测尿CTX-II、血清PIIANP和MMP-3,发现各标志物异常值比例基线为9.29%、1.97%、12.42%,u-CTX-II和s-MMP-3异常状态持续性强,而s-PIIANP仅15.38%持续异常;u-CTX-II异常与年轻、伤后手术时间短、低BMI和男性独立相关。
要点
- 基线u-CTX-II异常值占9.29%,s-PIIANP占1.97%,s-MMP-3占12.42%。
- 基线u-CTX-II异常者88.3%在未来时间点仍异常,s-MMP-3为82.93%,s-PIIANP仅15.38%。
- 年轻、伤后手术时间短、低BMI和男性与基线u-CTX-II异常独立相关(Tjur R2=0.598)。
核心结论
- 前交叉韧带重建后检测3种软骨代谢全身生物标志物均观察到异常值患者。
- s-PIIANP和s-MMP-3的异常状态难以由患者或手术因素解释,而u-CTX-II异常状态可部分由患者和手术因素解释。
- 结果支持纵向生物标志物分析,因为异常状态可随时间变化,横断面设计可能无法识别。
研究设计与样本
- 队列研究,证据等级2。
- 纳入前瞻性纵向研究中的患者,在初次前交叉韧带重建术前及术后6、12个月采集尿液和血清样本。
- 共666例患者提供样本,平均年龄24.9岁,男性占60.5%。
- 采用免疫分析法检测尿CTX-II、血清PIIANP和血清MMP-3浓度。
- 异常值定义为各生物标志物高于第3四分位数加1.5倍四分位距;采用多变量逻辑回归模型,以生物标志物异常状态为因变量,患者、损伤和手术因素为解释变量。
主要发现
- 基线时异常值比例:u-CTX-II为9.29%,s-PIIANP为1.97%,s-MMP-3为12.42%。
- 基线u-CTX-II异常患者中88.3%在未来一个或两个时间点仍为异常;s-MMP-3为82.93%;s-PIIANP仅15.38%。
- 基线非异常患者在未来时间点变为异常的情况不常见:u-CTX-II为6.83%,s-PIIANP为2.32%,s-MMP-3为2.08%。
- 患者和手术因素对s-PIIANP(Tjur R2=0.056)和s-MMP-3(Tjur R2=0.013)异常与非异常的区分能力差。
- 对u-CTX-II(Tjur R2=0.598),较年轻、伤后手术时间较短、较低体重指数和男性与基线u-CTX-II异常浓度独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Changes in systemic biomarkers of chondral metabolism have been identified after anterior cruciate ligament (ACL) reconstruction. Patients with extremely high biomarker concentrations (outlier patients) are often observed and may represent a group at high risk for posttraumatic arthritis. It is unclear if outlier status changes over time, and if it can be explained by patient, injury, and surgical factors. PURPOSE: To evaluate outlier status changes over time for 3 biomarkers of chondral metabolism after ACL injury and reconstruction and describe factors associated with outlier status. STUDY DESIGN: Cohort study; Level of evidence, 2. METHODS: Patients from a prospective longitudinal study were included. Urine and serum samples were taken immediately before primary ACL reconstruction and at 6 and 12 months postoperatively. A total of 666 patients provided samples (mean age, 24.9 years; 60.5% male). Concentrations of urinary C-terminal cross-linked telopeptide of type 2 collagen (u-CTX-II), serum N-propeptide of collagen 2A (s-PIIANP), and serum matrix metalloproteinase 3 (s-MMP-3) were measured using immunoassays. Outlier status was defined as values above quartile 3 plus 1.5 times the interquartile range for each biomarker. Multivariable logistic regression models were developed with biomarker outlier status as the dependent variable and patient, injury, and surgical factors as explanatory variables. RESULTS: At the baseline time point, the proportion of outliers was 9.29% for u-CTX-II, 1.97% for s-PIIANP, and 12.42% for s-MMP-3. Outlier patients at baseline were commonly also outliers at one or both of the future time points in terms of u-CTX-II (88.3%) and s-MMP-3 (82.93%). In contrast, for s-PIIANP outlier patients at baseline, only 15.38% were outliers at a future time point. It was uncommon for nonoutlier patients at baseline to become an outlier at either of the future time points (u-CTX-II: 6.83%; s-PIIANP: 2.32%; s-MMP-3: 2.08%). Patient and surgical factors had poor ability to discriminate between outlier and nonoutlier patients for s-PIIANP (Tjur R2 = 0.056) and s-MMP-3 (Tjur R2 = 0.013). However, for u-CTX-II (Tjur R2 = 0.598), younger age, shorter time from injury to surgery, lower body mass index, and male sex were independently associated with outlier u-CTX-II concentrations at baseline. CONCLUSION: Outlier patients were observed when measuring all 3 systemic biomarkers of chondral metabolism after ACL reconstruction. For s-PIIANP and sMMP-3, outlier status was poorly explained by patient or surgical factors, but for u-CTX-II, outlier status could, in part, be explained by patient and surgical factors. These results support longitudinal biomarker analyses, given that outlier status can change over time, and this may not be identified in cross-sectional study designs.
引用
- Batty LM, Huynh M, Webster KE, et al. An Exploration of Outlier Patients in Systemic Biomarkers of Chondral Metabolism After Anterior Cruciate Ligament Reconstruction. Am J Sports Med. 2025. PMID: 41103047. doi:10.1177/03635465251383532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。